

ABSTRACT

Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRF₁ receptors, including human CRF₁ receptors.

The invention thus includes methods for treatment of disorders and diseases associated
5 with CRF₁ receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.